The UK National Institute of Health and Care Excellence (NICE) has revised its type 2 diabetes guidelines to give more prominence to sodium-glucose cotransporter 2 (SGLT-2) inhibitor drugs as a treatment option. While a warning about the association of these drugs with diabetic ketoacidosis (DKA) remains, the guidelines offer stronger support of these drugs as treatments. Currently there are three drugs in this class available: canagliflozin (Invokana, Invokamet, Janssen), dapagliflozin (Farxiga, Xigduo XR, AstraZeneca), or empagliflozin. Read more